Reportlinker Adds World Multiple Myeloma Therapeutics Market Report

NEW YORK--(Business Wire)--
Reportlinker.com announces that a new market research report is available in its
catalogue.

World Multiple Myeloma Therapeutics Market

http://www.reportlinker.com/p0119496/World-Multiple-Myeloma-Therapeutics-Market.html

This report analyzes the US market for Multiple Myeloma Therapeutics in Millions
of US$. TThe market for multiple myeloma therapeutics is analyzed by the
following Drugs: Thalomid, Revlimid, Velcade, and Others. The market for
multiple myeloma therapeutics is also analyzed by the Lines of Treatment -
Induction Therapy for SCT Candidates, Induction Therapy for Non-SCT Candidates,
and Therapy for Relapsed or Refractory Myeloma. Annual forecasts are provided
for the period of 2006 through 2015. The report profiles 98 companies including
many key and niche players such as Amgen Inc., Avalon Pharmaceuticals, Inc.,
Bristol-Myers Squibb Company, Kosan Biosciences, Inc., Celgene Corporation, F.
Hoffmann-La Roche Ltd, Genentech, Inc., Genta Incorporated, Millennium
Pharmaceuticals, Ortho Biotech Products, LP, Seattle Genetics, and Ziopharm
Oncology, Inc. Market data and analytics are derived from primary and secondary
research. Company profiles are mostly extracted from URL research and reported
select online sources.

MULTIPLE MYELOMA THERAPEUTICS

A US MARKET REPORT MCP-1857

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. A US MARKET REPORT

1. Industry Overview II-1

Hematological Cancer Therapies: A Prelude II-1

Treatment Regimes: The Golden Rule II-1

Multiple Myeloma: A Second Most Common Hematological Cancer II-2

Table 1: Hematological Malignancies in the US (2007): Number

of Incidences and Deaths by Type of Cancer - Lymphoma

(Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma), Multiple

Myeloma, Leukemia (Acute Lymphocytic Leukemia, Chronic

Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid

Leukemia, and Other Leukemia), and Myelodysplastic Syndromes

(MDS) (includes corresponding Graph/Chart) II-3

Table 2: Blood Cancer Statistics in the US (2008E):

Percentage Breakdown of Hematological Cancer Cases by Type:

Lymphoma, Myeloma, and Leukemia (includes corresponding

Graph/Chart) II-3

Table 3: Multiple Myeloma Statistics in the US (2008E):

Number of Persons Undergoing Initial Diagnosis and Monitoring

(includes corresponding Graph/Chart) II-4

Treatment Therapies: Move Up the Learning Curve II-4

Risk-Adapted Therapy: The New Norm of Future Treatment II-5

New Generation Drugs in the Arsenal Against Multiple Myeloma II-5

Velcade (Bortezomib) II-5

Thalomid (Thalidomide) II-5

Revlimid (Lenalidomide) II-6

Alkeran (Melphalan) II-6

Doxil (Liposomal Doxorubicin) II-6

Trisenox (Arsenic trioxide) II-6

Noteworthy Issues Related to Major Drugs: An Evaluation of

Pros and Cons II-7

Revlimid Overtakes Thalomid: Why? II-7

How Effective Will Thalomid Be in the 3rd Line Setting?

Skepticism Overflows II-7

Revlimid Impedes Stem Cell Harvesting!!: What`s the Truth? II-7

1st & 2nd Generation Geldanamycin Analog to Do Wonders for

Myeloma Treatment II-8

Other Trends & Issues II-8

Approval of New Generation Drugs Push the Market Into the

Bulge Bracket II-8

Growth Fundamentals Get Stronger II-8

Table 4: Key Drug Regimens in the US Multiple Myeloma

Market (2006): Breakdown of Typical Length of Treatment

Cycle and Cost per Cycle (In US$) (includes corresponding

Graph/Chart) II-9

Multidrug Resistance: A Challenge to Reckon With II-9

Gene Therapy Exudes Hope II-9

Challenges Encountered in Clinical Trials II-10

FDA`s Antidotes II-10

Europe Lagging Behind in Drug Approvals II-11

Table 5: Multiple Myeloma Market in Europe (2006):

Percentage Breakdown of Drugs Used in First Line Treatment -

Melphalan, Thalidomide, Velcade, Doxorubicin, and Others

(includes corresponding Graph/Chart) II-11

Table 6: Multiple Myeloma Market in Europe (2006):

Percentage Breakdown of Drugs Used in Second Line Treatment -

Melphalan, Thalidomide, Velcade, and Doxorubicin

(includes corresponding Graph/Chart) II-11

Table 7: Multiple Myeloma Market in Europe (2006):

Percentage Breakdown of Drugs Used in Third Line Treatment -

Melphalan, Thalidomide, Velcade, Doxorubicin, and Others

(includes corresponding Graph/Chart) II-12

Market Share Statistics II-12

Present Batting Order II-12

Table 8: US Market for Multiple Myeloma Therapeutics

(2006): Percentage Breakdown of Revenues by Company -

Celgene Corporation, Millennium Pharmaceuticals,

Ortho-Biotech, and Others (includes corresponding

Graph/Chart) II-12

Looking Through the Crystal Ball: Year 2013 II-12

Table 9: US Market for Multiple Myeloma Therapeutics

(2013P): Percentage Breakdown of Revenues by Company -

Celgene Corporation, Millennium Pharmaceuticals Inc, Kosan

Biosciences, Ortho Biotech, Ziopharm Oncology Inc and

Others (includes corresponding Graph/Chart) II-12

Oncology and Hematology Market II-13

Table 10: Leading Players in the Oncology and Hematology

Market in the US (2008E): Percentage Breakdown of Value

Sales by Company - Amgen, Roche, Novartis, DNA,

AstraZeneca, and Others (includes corresponding

Graph/Chart) II-13

Drugs Approved & In Pipeline: A Review II-13

Multiple Myeloma Drugs Approved by the FDA As of the Year 2008 II-13

Multiple Myeloma Drugs in Pipeline in the US As of the Year

2008 II-14

Phase III Drugs in Pipeline II-14

Phase II Drugs in Pipeline II-15

Phase I Drugs in Pipeline II-21

Key Non-Profit Organizations in the US II-25

Multiple Myeloma Research Foundation (MMRF) II-25

National Coalition for Cancer Survivorship (NCCS) II-25

National Marrow Donor Program (NMDP) II-25

Oregon Health and Science University Cancer Institute II-25

2. Disease & Treatment Overview II-26

Cancer: A Definition II-26

Hematological Cancers II-26

Types of Hematological Cancer II-26

Multiple Myeloma II-26

Multiple Myeloma Stages II-27

Stage I II-27

Stage II/III II-27

Treatment Procedures II-27

Diagnosis II-27

Treatment II-28

Initial Treatment Regimen II-28

Induction Therapy for SCT Candidates II-28

Induction Therapy for Non-SCT Candidates II-29

Therapy for Relapsed or Refractory Myeloma II-29

Maintenance Therapy for Relapsed or Refractory Myeloma II-29

Treatment Pros & Cons II-29

Others Types of Hematological Cancers II-30

Leukemia II-30

Acute Lymphocytic Leukemia II-30

Chronic Lymphocytic Leukemia II-31

Acute Myeloid Leukemia II-31

Chronic Myeloid Leukemia II-31

Lymphoma II-31

Non-Hodgkin`s Lymphoma II-32

Hodgkin`s Lymphoma II-32

Myelodysplastic Syndromes II-32

Hematological Cancer Therapies II-33

Chemotherapy II-33

Radiation Therapy II-33

Stem Cell Transplants II-33

Biological Therapy II-34

Targeted Therapy II-34

Gene Therapy II-34

Immunotherapy II-34

Monoclonal Antibody Treatment II-35

Vaccines II-35

Donor Lymphocyte Infusion II-35

Hematological Cancer Drug Classes II-35

Hypomethylating Agents & Antimetabolites II-35

Bisphosphonates II-36

Alkylating Agents and DNA-Damaging Agents II-36

DNA-Repair Enzyme Inhibitors II-36

Histone Deacetylase Inhibitor II-36

Immunomodulators II-36

Proteasome Inhibitor II-36

Tyrosine Kinase Inhibitors II-36

3. Clinical Trials and Drug Approvals II-37

NICE Grants Approval for Use of Revlimid II-37

SWOG Announces Closure of Phase III Trial (S0232) for Paitents

with Multiple Myeloma II-37

Fujimoto Pharmaceutical Receives Approval to Market Thalidomide II-37

Celgene Obtains Health Canada Approval for Revlimid Oral

Cancer Drug II-37

FDA Grants Orphan-Drug Designation to Melphalan II-38

Merck Commences Phase II-b and Phase III Clinical Trial of

Zolinza II-38

Clavis Initiates Phase II Trial of Elacytarabine II-38

Gilead Sciences Commences GS 9219 Phase I Clinical Trial II-38

AstraZeneca Carries Out AZD 0530 Phase II trial II-39

European Commission Grants Approval of Thalidomide for

Multiple Myeloma II-39

EMEA Issues Positive Opinion for Thalidomide Use in Multiple

Myeloma II-39

Global Regulatory Developments for the Use of Revlimid in

Multiple Myeloma II-39

Takeda Gains FDA Approval to Promote Velcade II-40

Health Canada Approves VELCADE II-40

Genzyme Receives FDA Certification for Mozobil II-40

Celgene`s Thalidomide Pharmion Receives Marketing Authorization II-41

Ziopharm Commences Phase II Clinical Trial of ZIO-101 II-41

FDA Approves Pluristem`s Pre-IND Application of PLX-I II-41

Merck Pharmaceuticals Commences Phase I Study for R763 Kinase

Inhibitor II-41

Swissmedic Approves Celgene`s REVLIMID Oral Cancer Drug II-42

Celgene`s REVLIMID Receives EU`s Marketing Authorization II-42

FDA Approves Application of Piramal`s IND-P276 Multiple

Myeloma Drug II-42

Millennium Pharmaceuticals and Johnson & Johnson Initiate

Velcade Phase II Trial II-42

FDA to Consider the New Drug Application Filed for Use of

Doxil Combined with Velcade in Patients with Multiple

Myeloma II-42

Ortho Biotech Files Application with FDA for Approval of

Combination Drug DOXIL and VELCADE II-43

Caraco`s Allopurinol Receives FDA Approval II-43

FDA Approves Thalomid as Combination Therapy for Multiple

Myeloma II-43

Revlimid Obtains Regulatory Approval for the Treatment of

Multiple Myeloma II-43

LymphoSign Inc. Announces Successful Completion of LS104

Drug`s Pre-Clinical Testing II-43

Seattle Genetics Commences SGN-40 Phase I Clinical Trial II-44

FDA Approves Use of Revlimid for Multiple Myeloma II-44

US FDA Approves Use of Thalidomide for Multiple Myeloma II-44

Ziopharm Oncology Receives Approval to Commence ZIO-101 and

ZIO-201 Trial II-44

FDA Grants Approval for Use of VELCADE for Patients with

Mantle Cell Lymphoma II-44

4. Recent Industry Activity II-45

CytRx to Acquire Innovive II-45

Launch of Epoetin alfa Hexal II-45

PDL and Bristol-Myers Signs Agreement II-45

MNKD and LLS Conclude Joint Research Agreement II-45

MorphoSys and DSM Enter into Agreement II-46

StemCyte Enters into Joint Venture with Cadila and Apollo

Hospitals in India II-46

ImmunoCellular Acquires Molecular Antibody Technology II-46

US House of Representatives Sanction the Hematological Cancer

Research Investment and Education Act II-46

Bayer and Cell Therapeutics Enter into Mutual Agreement II-47

Bristol-Myers to Take Over Kosan Biosciences II-47

Bristol and PDL BioPharma Enter into Agreement II-47

Gamida Cell Enters Into a Agreement with Amgen II-47

Circadian Acquires Complete Stake in Vegenics II-48

Takeda Acquires Millennium Pharmaceuticals II-48

GlaxoSmithKline Forms Alliance with OncoMed for Developing

Cancer Therapeutics II-48

Cyclacel Signs Agreement to Acquire ALIGN Pharmaceuticals II-49

Biogen and Genentech to Jointly Develop and Commercialize New

Blood Cancer Drug II-49

Aegera Therapeutics Acquires LymphoSign Inc II-49

Velcade Gains Subsidy II-50

Inex Pharmaceuticals Spins Off Biotechnology Business into

Tekmira Pharmaceuticals II-50

MilleGen Enters into Collaboration with LFB II-50

Access Pharmaceuticals to Acquire Somanta II-50

TopoTarget to Acquire Apoxis SA II-51

Genentech Inks Exclusive Global Licensing Agreement with

Seattle Genetics II-51

Celgene Agrees to Acquisition of Pharmion II-51

PerkinElmer Plans Acquisition of ViaCell II-51

Favrille Announces Acquisition of Monoclonal Antibody Range

from Diversa II-52

Johnson & Johnson Secures Contract worth US$112 Million II-52

Bioniche Pharma to Acquire Branded Pharmaceutical from Nabi

Biopharmaceuticals II-52

Takara Bio's RetroNect Used for Clinical Trials of Gene

Therapy in Australia II-52

Millennium Pharmaceuticals to Take Over AnorMED II-53

MDS Pharma Services Becomes Recommended CRO for Multiple

Myeloma Drug R&D II-53

Celgene Certifies McKesson Specialty to Launch Revlimid II-53

Medarex and PacMab to Co-Develop Blood Cancer Therapies II-53

Gamida Cell and Teva to Co-Develop Therapy for Hematological

Malignancies II-54

GlaxoSmithKline to Take Over Praecis Pharmaceuticals II-54

Biotest Acquires ImmunoGen Anticancer Technology Rights II-54

Hana Signs Licensing Agreement with Inex II-54

Cephalon Acquires Zeneus II-54

5. Focus on Select Players II-55

Amgen Inc (USA) II-55

Avalon Pharmaceuticals, Inc. (USA) II-55

Bristol-Myers Squibb Company (USA) II-55

Kosan Biosciences, Inc. (USA) II-55

Celgene Corporation (USA) II-56

F. Hoffmann-La Roche Ltd (Switzerland) II-56

Genentech, Inc. (USA) II-56

Genta Incorporated (USA) II-56

Millennium Pharmaceuticals (USA) II-57

Ortho Biotech Products, LP (USA) II-57

Seattle Genetics (USA) II-57

Ziopharm Oncology, Inc. (USA) II-57

6. Market Perspective II-59

Table 11: US Recent Past, Current & Future Analysis for

Multiple Myeloma Therapeutics by Drug - Thalomid, Revlimid,

Velcade, and Others Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) II-59

Table 12: US 10-Year Perspective for Multiple Myeloma

Therapeutics by Drug - Percentage Breakdown of Dollar Sales

for Thalomid, Revlimid, Velcade, and Others for Years 2006,

2009 & 2015 (includes corresponding Graph/Chart) II-59

Table 13: US Recent Past, Current & Future Analysis for

Multiple Myeloma Therapeutics by Line of Treatment - Induction

Therapy for SCT Candidates, Induction Therapy for Non-SCT

Candidates, and Therapy for Relapsed or Refractory Myeloma

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2006 through 2015 (includes corresponding

Graph/Chart) II-60

Table 14: US 10-Year Perspective for Multiple Myeloma

Therapeutics by Line of Treatment - Percentage Breakdown of

Dollar Sales for Induction Therapy for SCT Candidates,

Induction Therapy for Non-SCT Candidates, and Therapy for

Relapsed or Refractory Myeloma for Years 2006, 2009 & 2015

(includes corresponding Graph/Chart) II-60

III. COMPETITIVE LANDSCAPE

To order this report:

World Multiple Myeloma Therapeutics Market

http://www.reportlinker.com/p0119496/World-Multiple-Myeloma-Therapeutics-Market.html

More market research reports here!

Reportlinker
Nicolas: nbo@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

Copyright Business Wire 2009